Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT02663973 Completed - Breast Cancer Clinical Trials

Prospective Evaluation of Breast Cancer at Brazilian Institutions - Project AMAZONA III

Start date: January 1, 2016
Phase:
Study type: Observational

The principal goal of this study is to describe the epidemiology of breast cancer in the Brazilian population

NCT ID: NCT02662868 Completed - Clinical trials for Metastatic Breast Cancer

Metastatic Breast Cancer in Brazil: Characterization of Patients and Treatments

Start date: June 2015
Phase: N/A
Study type: Observational

The purpose of this study is to describe demographics and socioeconomics characteristics associated to the diagnosis of metastatic breast cancer in Brazil.

NCT ID: NCT02662335 Completed - Clinical trials for Stage IIIA Breast Cancer

Computerized Cognitive Retraining in Improving Cognitive Function in Breast Cancer Survivors

Start date: May 2016
Phase: N/A
Study type: Interventional

This randomized clinical trial studies computerized cognitive retraining in improving cognitive function in breast cancer survivors. Cancer-related cognitive deficits, such as thinking and memory issues, are common among breast cancer survivors. The severity of these cognitive deficits is associated with a significant negative impact on daily function and quality of life. A computerized cognitive retraining method may help researchers find ways to improve cognitive function and quality of life in breast cancer survivors.

NCT ID: NCT02659514 Completed - Breast Cancer Clinical Trials

Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer

Start date: February 22, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to establish the dose regimen and evaluate the preliminary efficacy and the safety/tolerability of poziotinib in participants with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have received at least two prior HER2-directed treatment regimens.

NCT ID: NCT02658734 Completed - Clinical trials for HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer

A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane

Start date: November 1, 2016
Phase: Phase 4
Study type: Interventional

This is a Phase IV, single-arm, multicenter, open-label clinical trial designed to assess the safety of trastuzumab emtansine in Indian patients with HER2-positive unresectable locally advanced breast cancer (LABC) or metastatic breast cancer (mBC) who have received prior treatment with trastuzumab and a taxane.

NCT ID: NCT02658708 Completed - Breast Cancer Clinical Trials

Bright Light on Fatigue in Women Being Treated for Breast Cancer

Start date: October 12, 2015
Phase: Phase 1
Study type: Interventional

This proposed study will examine feasibility and implement therapeutic bright light that is tailored to the individual's circadian typology to estimate its therapeutic effects on sleep/wake patterns and fatigue in breast cancer patients undergoing chemotherapy.

NCT ID: NCT02658461 Completed - Breast Cancer Clinical Trials

An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)

Start date: February 2012
Phase: N/A
Study type: Observational

This prospective, non-interventional time and motion study will evaluate the costs of healthcare resource utilization associated with the administration of trastuzumab (Herceptin) SC and IV formulations in HER2-positive EBC. This is a sub-study of the clinical study MO22982 (NCT01401166/PrefHer).

NCT ID: NCT02658214 Completed - Clinical trials for Esophageal Squamous Cell Carcinoma

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Start date: April 28, 2016
Phase: Phase 1
Study type: Interventional

Durvalumab and Tremelimumab in combination with first-line chemotherapy in the following indications: Ovarian/peritoneal/fallopian tube cancer, SCCHN, TNBC, SCLC and gastric/GEJ cancer, PDAC, ESCC.

NCT ID: NCT02657993 Completed - Breast Neoplasms Clinical Trials

Hypnosis to Reduce Aromatase Inhibitor Pain and Improve Adherence

Start date: March 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether hypnosis is efficacious in reducing musculoskeletal pain in breast cancer survivors taking aromatase inhibitors, and by doing so, whether hypnosis can help survivors to be more adherent to their medication regimen.

NCT ID: NCT02657889 Completed - Breast Cancer Clinical Trials

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer

TOPACIO
Start date: April 15, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This Phase 1/2 study will evaluate the safety and efficacy of combination treatment with niraparib and pembrolizumab (MK-3475) in patients with advanced or metastatic triple-negative breast cancer or recurrent ovarian cancer. (KEYNOTE-162)